Reneuron Group (RENE)

 

RENE Share PerformanceMore

52 week high5.5000 27/08/15
52 week low2.2615 08/12/15
52 week change -2.4500 (-47.12%)
4 week volume27,772,635 28/07/16

Media for (RENE)

Presenter: Michael Hunt, CEO
04/02/2015

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Posting of Annual Report and Notice of AGM

RNS Number: 4560G ReNeuron Group plc 05 August 2016 5 August 2016 AIM: RENE ReNeuron Group plc ("ReNeuron" or the "Company") Posting of Annual Report and Accounts and Notice of AGM ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that its Annual Report and Accounts for the...

Stroke clinical data published in The Lancet

RNS Number: 1850G ReNeuron Group plc 04 August 2016 4 August 2016 AIM: RENE ReNeuron Group plc Stroke clinical data published in The Lancet Published long term Phase I data show evidence of improvements in neurological function sustained out to 24 months and good safety profile ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based globa...

Publication of positive pre-clinical retinal data

RNS Number: 9275E ReNeuron Group plc 22 July 2016 AIM: RENE 22 July 2016 ReNeuron Group plc Publication of positive pre-clinical data from retinal stem cells ReNeuron's hRPC stem cells arrest visual decline in pre-clinical models of retinal degeneration, demonstrating their therapeutic potential ReNeuron Group plc (the "Company") (AIM: RENE), a UK-bas...

Directors' Interest in Shares and Share Options

RNS Number: 7721E ReNeuron Group plc 20 July 2016 20 July 2016 AIM: RENE ReNeuron Group plc Directors' Interest in Shares and Share Options ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that on 19 July 2016 , the following awards were made under the Compan...

Preliminary Results

RNS Number: 4822D ReNeuron Group plc 07 July 2016 7 July 2016 AIM: RENE ReNeuron Group plc ("ReNeuron" or "the Company") Preliminary Results for the Year Ended 31 March 2016 ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce its preliminary results for the year ended 31 ...

Notification of Preliminary Results

RNS Number: 0550B ReNeuron Group plc 14 June 2016 14 June 2016 AIM: RENE ReNeuron Group plc ("ReNeuron" or "the Company") Notification of Preliminary Results ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics , will announce its preliminary results for the year ended 31 March 2016 on Thursday ...

Reuron says patient recruitment completed in stroke trial

ReNeuron has completed patient recruitment in the Phase II clinical trial (PISCES II) of its CTX cell therapy candidate in p...

Patient recruitment completed in stroke trial

RNS Number: 9395A ReNeuron Group plc 13 June 2016 13 June 2016 AIM: RENE ReNeuron Group plc Patient recruitment completed in Phase II stroke clinical trial ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to provide an update on progress with its stroke programme. The C...

Fundamental DataMore

EPS-0.4
Dividend yield0 %

Equity Research (RENE)

edison investment research
ReNeuron Group plc
05/08/2016
ReNeuron has announced the publication of long-term Phase I stroke clinical trial (PISCES-I) data in The Lancet. The data indicate improvements in neurological status and limb function compared with...
edison investment research
ReNeuron Group plc
27/07/2016
Investor focus is currently on the readout of ReNeuron’s Phase II stroke disability study with its CTX cells, due in Q416. Alongside this there are a number of other data readouts and progression of...
edison investment research
ReNeuron Group plc
24/03/2016
ReNeuron has treated the first patient in its US Phase I/II clinical trial with its cell therapy candidate for the blindness-causing disease retinitis pigmentosa (RP). This is a significant step...

Latest discussion posts More

  • Re: The Lancet

    bit more here Hopeful early results for stem cell implantation in chronic stroke A first-in-man study of neural stem cell transplantation has found no safety issues and ...
    23-Aug-2016
    mol42
  • Re: The Lancet

    Cheers Jaw74 a bit more of an insight - many thanks for taking the time to post mol
    23-Aug-2016
    mol42
  • Re: The Lancet

    Hi Mol, I copy below an extract from the Lancet relating to efficacy. "Our secondary endpoints were exploratory indices of efficacy. Given the small number of patients, ...
    23-Aug-2016
    JAW74

Users' HoldingsMore

Users who hold Reneuron Group also hold..
LLOYDS GRP.17%
BARCLAYS13%
BP13%
ROYAL BANK SCOT10%
GLAXOSMITHKLINE10%

Codes & Symbols

ISINGB00B0DZML60
SymbolsRENE, LSE:RENE, RENE.L, RENE:LN, LON:RENE, XLON:RENE